Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.…
Major Memphis Health System Expands BVA® Adoption to New Hospital Outpatient Site
Daxor (NASDAQ: DXR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector.
The shares were at 7.450 USD on 20 November 2026, down 44.3% over 52 weeks. Its 52-week range is 7.000 USD to 14.76 USD: the price is 49.5% below the high and 6.4% above the low.
At a market capitalisation of 43.49M USD, it trades at 6.8 times trailing earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 86% for DXR.
Daxor reports return on equity of 20.0% and revenue up 25.5% year over year.
Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 20.00 USD is 168.5% above the current price.